Introduction
Feline leukaemia viruses (FeLV) are horizontally transmitted type C oncoretroviruses, which lead to persistent infection of domestic cats (Jarrett et al., 1964; Hardy et al., 1973) . After primary infection, the virus first replicates in the oropharynx. Then the lymph nodes, thymus and Peyer's patches are infected and the virus progresses to the bone marrow, where neutrophils and thrombocytes are the preferential target cells (Rojko et al., 1979) . Most cats develop antibodies after transient viraemia and acquire immunity, although about 15 ~o of cats remain viraemic during their lifetime (Jarrett & Golder, 1982) , the majority of which die of aplastic anaemia, or of opportunistic infections due to the immunosuppressive properties of FeLV. A minority develop lymphosarcomas of the thymus and, less frequently, myeloid or erythroid leukaemia (Hardy, 1980) . The three FeLV subgroups A, B and C are characterized by the seroreactivity of their external glycoproteins gp70 (Sarma & Log, 1973) . FeLV-A is the subgroup most frequently isolated, whereas FeLV-B occurs only in association with FeLV-A. FeLV-C is rarely found and then either together with FeLV-A, or with FeLV-A and FeLV-B. After experimental infection both FeLV-A and FeLV-B induce tumours, but FeLV-C seems to be associated with aplastic anaemia (Jarrett et al., 1978) .
Various approaches to vaccination against FeLV infection have been reported, including those which used complex vaccines such as complete formalin-or u.v.-inactivated virus (Olsen et al., 1976; Schaller et al., 1977) , or crude and rather undefined subunit preparations (Mastro et al., 1986) . With all these preparations the protection given was weak, non-existent or even an enhancement of the susceptibility to FeLV disease was achieved. The purified monomeric external glycoprotein gp70 also failed to protect against viraemia (Salerno et al., 1978) . From experiments with the closely related Friend erythroleukaemia virus (F-MuLV) it is known that the amount of purified gp70 used for vaccination is critical to achieve protection and may have been too low in previous experiments. Moreover, aggregated gp85 or gp70 coupled to carriers is more immunogenic than soluble gp70 (Hunsmann et al., 1981; Kleiser et al., 1986) . Prophylactic immunization of cats with FeLV gp85 rosettes reduced the growth of feline sarcoma virus (FeSV)-induced sarcoma . In a
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S. Nick and others more recent trial a protective immune response was induced by vaccination with FeLV immunostimulating complexes (Osterhaus et al., 1985) . Although therapy with a high titre goat antiserum to FeLV protected against death from development of progressive FeSVinduced tumours (De Noronha et al., 1977) , passive immunization with FeLV neutralizing monoclonal antibodies (MAbs) was not effective (Weijer et al., 1986) . In general, most of these experiments have shown that the glycoprotein gp85 is a major target of an immune attack that can mediate protection against FeLV and FeSV infection and diseases. Synthetic peptides corresponding to potential antigenic sites may be useful tools for the immunological characterization of gp85. In addition, peptides mimicking epitopes of defined antigenicity are candidate antigens for incorporation into a synthetic vaccine, as shown earlier using Friend murine leukaemia virus (Bayer & Hunsmann, 1987) . Such a subunit vaccine preparation has a distinct advantage, as the region of pl5E that suppresses the immune response (Snyderman & Cianciolo, 1984) and antigenic sites inducing enhancing antibodies can be excluded.
Here we report on the identification of functional antigenic determinants of FeLV gp70 and pl5E, employing sequence-homologous synthetic peptides derived from the sequence of the Gardner-Arnstein strain of FeLV-B. Two epitopes capable of inducing crossneutralizing antibodies against FeLV subgroups A, B and C were mapped on gp70 and one epitope was identified on pl5E. Surprisingly, two domains of gp70 and two domains of pl5E induced infection-enhancing antibodies. In addition, the capacity of the antipeptide sera to mediate complement-dependent cellular cytotoxicity was investigated.
Methods
Cells and viruses. FL74 cells (Theilen et al., 1969) and a feline renal cell line (CRFK) (CrandaU et al., 1973) were grown in Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine calf serum and 2 mM-glutamine. FeLV was harvested from the supernatants of FL74 cells by differential centrifugation, as described previously (Moennig et al., 1974) .
Synthetic peptides and immunization schedules. Synthetic oligopeptides representing 16 potential antigenic epitopes of gp85 were chosen from the Gardner-Arnstein sequence of FeLV-B (W~nsch et al., 1983) . Two peptides were derived from FeLV-A (Stewart et al., 1986) and one from FeLV-C (Luciw et al., 1985) and the numbering of the amino acid positions refers to the Gardner-Arnstein sequence. Criteria for selection were described in detail by Bayer et aL (1984) , but the main methods were hydrophilicity calculations, as in Hopp & Woods (1981) and predictions of secondary structures, according to Chou & Fasman (1974) and Gamier et al. (1978) . Peptides were synthesized as described by Birr et al. (1978) and their purity was assessed by HPLC analysis.
For immunization of rabbits, the peptides were covalently linked to keyhole limpet haemocyanin (KLH), either by glutaraldehyde or by carbodiimide (Bayer et al., 1984) . The animals were inoculated with 1 mg of peptide-carrier conjugate emulsified in complete Freund's adjuvant (CFA) and after 4 weeks the rabbits were boosted and then bled 14 days later. To prepare an antiserum against p27, FeLV was separated on SDS-polyacrylamide gels. The p27 band was visualized by KCI staining (Hager & Burgess, 1980) and excised from the gel. The excised gel material was homogenized, emulsified in CFA and used for immunization of rabbits. The antiserum to gp85 has been described .
Titration ofantisera. Titres of antipeptide sera were determined by ELISA using synthetic peptides, whole virus, or purified gp85 as antigens . Pre-immune sera of individual rabbits were used as controls. In brief, microtitre plates were coated with synthetic peptides diluted in 50 mM-sodium carbonate buffer pH 9-6 at 65 °C for 8 h. Whole virus or purified gp85 was adsorbed overnight at 4 °C, plates were washed to remove unbound antigen, and incubated with the peptide antisera for 2 h at 37 °C. Then peroxidase-conjugated goat anti-rabbit IgG (Medac) was added and plates were kept for 1 h at 37 °C. Phenylenediamine and hydrogen peroxide were used as substrates and the absorbance was measured at 492 nm.
Immunoblotting procedures and proteolytic cleavage of gp70. Viral polypeptides were separated by electrophoresis on 9 to 16% polyacrylamide gels and transferred to nitrocellulose sheets by electropboresis at 250 mA (Towbin et al., 1979) . For proteolytic cleavage gp70 was excised from the gel, layered onto a 12 to 209/o SDS-polyacrylamide gel containing 1 ~ EDTA and partially digested with V8 protease (3 pg, 500 units/rag) (Boehringer Mannheim) (Cleveland et al., 1977) . Proteolytic fragments were transferred to nitrocellulose and the nitrocellulose sheets were saturated with phosphate-buffered saline (PBS) containing 0.3~ Tween 20 for 40 min at room temperature and cut into strips. Antipeptide sera were diluted twofold with PBS-Tween buffer and incubated for 2 h at 37 °C with the strips. Unbound antibody was washed off and a goat anti-rabbit IgG (Medac) was added for 1 h. The reaction was enhanced by a peroxidase-conjugated swine anti-goat IgG (Medac) and immune reactivity was detected with 4-chloro-1-naphtbol and hydrogen peroxide.
Purification of antibodies. Antibodies were purified from the sera either by fluid pressure liquid chromatography (FPLC) on a Mono Q column (Pharmacia), or by affinity chromatography on peptides coupled to CNBr-activated Sepharose 4B (Pharmacia). For binding of the peptide, 0.5 mg CNBr-Sepharose was incubated at room temperature in 1 mM-HC1 for 15min and thoroughly washed with HCI, 100 mM-sodium carbonate buffer pH 8.3 and 0-5 M-NaC1. Two mg of peptide was coupled to the pretreated Sepharose beads, at 4°C overnight. After treatment for 2 h with 0-1 M-Tris-HCI pH 8-0, the unbound peptide was removed by washing with 0.5 M-NaCI and 0.1 Macetate buffer pH 4.0. Antibodies were adsorbed for 4 h and the column was washed with PBS containing 0.5 ~ Tween 20 and finally with PBS. Antibodies were eluted with 0.1 M-glycine-HCl buffer pH 2.5. The fractions were neutralized with 0-5 M-Tris and analysed by PAGE. Antibody-containing fractions were pooled and concentrated by pressure dialysis.
Neutralization assay. Neutralization assays of antipeptide sera were performed on monolayers of CRFK cells. A cell suspension (100 ~tl) containing 20000 cells per ml was seeded into microtitre plates and 1 day later, cells were infected with supernatant of FL74 cells containing FeLV subtypes A, B and C (Sarma & Log, 1973) . The virus inoculum had been preincubated with the respective peptide antiserum for 30 min at 37 °C and cells were fixed with methanol after 6 days. To determine p27 expression by ELISA , cells were incubated with a mixture of two monoclonal anti-p27 antibodies for l h (Lutz et al., 1983) . Afterwards, unbound antibodies were removed by washing and peroxidase-conjugated goat anti-mouse IgG (Medac) was added for 1 h. The ELISA was developed as described above.
Complement-dependent cellular cytotoxicity. To determine the complement-dependent cell lysis of antipeptide sera, chromium release assays (Hunsmann et al., 1976) were performed with FL74 cells labelled with 250 p.Ci Na2SlCrOa (Amersham). Maximum release was achieved by freezing and thawing the labelled cells three times and the percentage of specific release was calculated as 100 × (release in assay-spontaneous release)/(maximum release-spontaneous release).
Results

Synthetic peptides derived from FeL V subgroups A, B and C selected for investigation
The positions of the 19 oligopeptides selected for investigation are indicated in Fig. 1 . Peptides without letters did not induce antibodies to the glycoprotein or to whole virus. The exact amino acid numbering and sequences of the peptides, as well as virus subgroups, are shown in Table 1 .
Synthetic peptides induced antibodies reacting with gp85 and whole virus
Although the antibody responses among individual rabbits varied considerably, several reaction patterns could be observed. All antisera produced against peptides coupled to KLH reacted well with the corresponding peptide (Table 2) . To evaluate whether the peptides represent epitopes of the glycoprotein and the virus particle, we analysed the reactivity of the respective sera by ELISA, using gp85 or whole virus as antigens.
The majority of the antipeptide sera reacted with gp85, or virus, or both. Antisera to peptides A, B, E, F, G, K and L were highly effective against gp85 and peptides B, E, F, G and L yielded high antibody titres to gp85 and to the whole virus. Peptides C, D, H and J were weakly immunogenic, evoking ony low titres of antibody. Antisera to peptide M, derived from the A subtype, reacted poorly, although one antiserum against peptide N recognized both gp85 and whole virus well. Immunization of rabbits with peptide O, which included the sequences of D, E, F and K, resulted in high antibody titres against gp85. The reaction with whole virus was moderate.
The results of the ELISAs could be confirmed by Western blotting. Sera with high titres to glycoprotein or virus generally detected gp85, gp70 or pl5E on the nitrocellulose sheets (Table 2) , with the exception of antisera against peptides K and L. Sera with low ELISA antibody titres, i.e. antisera against peptides C, H, I or J, did not react with envelope glycoproteins. In addition, all antisera were tested for reactivity with protein fragments obtained by cleavage of gp70 with V8 protease (Table 2) . Interestingly, antibodies against peptide C detected proteolytic fragments, but did not react with uncleaved gp85 or gp70.
Epitopes mediating neutralization or enhancement can be defined on the external glycoprotein gp70 and on the transmembrane protein p15 E
For each peptide the antiserum with the highest titres of antibodies to gp85 and purified virus was selected and further characterized for neutralizing activity (Table 3) . Antiserum from rabbit 938 against peptide L, corresponding to a sequence on pl5E, neutralized viral infection completely at a dilution of 1:5. Serum from rabbit 287 against peptide D showed neutralizing capacity only after FPLC purification of antibodies, and serum from rabbit WN3 against peptide G mediated neutralization after affinity purification of antibodies on the peptide coupled to Sepharose. In both cases untreated sera did not affect p27 expression. Interestingly, antisera against peptides C, F, J and K even enhanced viral infectivity at dilutions from 1 : 5 to 1 : 125. The same was observed with an antiserum against peptide G from rabbit WN4. Pre-immune sera were not effective. In addition, the capacity of the antisera to mediate complement-dependent cytotoxicity was investigated. Even when diluted 1:2500, the antiserum against gp85 induced specific chromium release. None of the peptide antisera, or mixtures of them, exhibited cytotoxic activity and the release of 5tCr for pre-immune and immune sera of individual rabbits ranged between 2~ and 5 ~ (data not shown).
Discussion
Using the algorithms of Hopp & Woods (1981) , Chou & Fasman (1974) and Gamier et al. (1978) we have predicted several antigenic domains of the glycoprotein Fourteen peptides induced antibodies against purified gp85 or whole virus, indicating that they represent natural epitopes of the viral glycoprotein. Antibodies against peptide F recognized isolated gp85 and whole virus, whereas antibodies against the shorter peptides D and E only reacted with the purified glycoprotein. These results imply that the conformation of the longer peptide mimics more accurately the original structure of this amino acid sequence in the virus particle. We assume that this part of gp85 undergoes a conformational change during the purification procedure, which might enable antibodies elicited by the shorter peptides to bind. The phenomenon that antibodies induced with synthetic oligopeptides show a stronger reaction with isolated gp85 than with purified virus particles was also observed with antisera against peptides A and I. One possible explanation could be another conformational change, as discussed above; another reason might be the manner of insertion of the glycoprotein into the viral membrane. On purified gp85 there are several antigenic sites that are probably masked on virus-bound gp85 and these could become accessible to antibodies.
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protease lragments obtained by cleavage of gp70.
Antibodies against peptides C and K detected proteolytic fragments, but did not react with gp85 or gp70 on the nitrocellulose sheets. Thus, the epitopes represented by these peptides were accessible on the fragments, but probably hidden on the uncleaved polypeptides. Two epitopes critical for neutralization were defined on the outer membrane protein gp70 by peptides D and G. The epitope represented by peptide D, amino acids 221 to 227, is part of the major neutralizing epitope described by Nunberg et al. (1984) that includes amino acids 213 to 226 and is also part of the epitope from amino acids 221 to 237, identified by Elder et al. (1987) .
This finding shows that, as well as the region from amino acids 213 to 217 recognized by a neutralizing monoclonal antibody, Nunberg's peptide contains a second site A new third epitope, corresponding to peptide L, was identified on the membrane anchor pl5E, of which the tertiary structure is still unknown. Our data, based on the neutralization results and the hydropathy analysis, provide some evidence for the assumption that the carboxy terminus of the transmembrane protein is located on the envelope surface.
Several of the antisera actually enhanced viral infectivity. Similar phenomena are described for flaviviruses such as West Nile virus (Fagbami et al., 1988) and dengue virus (Halstead, 1988 ) that infect Fc receptor-bearing macrophages and also for the human immunodeficiency virus, HIV (Takeda et al., 1988) . For these viruses it is known that subneutralizing concentrations of antibodies cause an enhancement of the infection, via binding of antibody-virus complexes to cellular Fc receptors and these complexes facilitate the attachment of virus particles to target cells. Antisera against synthetic oligopeptides derived from F-MuLV gp70 (positions 283 to 290 and 434 to 441) (Bayer, 1985) and MAbs against murine retroviruses (Legrain et al., 1986 ) increase viral replication in vitro. The reason for this might be an aggregation of particles, thus enabling more infectious virions to bind to and penetrate into target cells. Another explanation could be conformational changes of the receptor-binding domain introduced by antibody binding to neighbouring epitopes. For these reasons, care should be taken not to induce only low levels of antibody with a synthetic peptide vaccine or any general vaccine. Low levels of antibody or antibodies that do not neutralize FeLV pre-existing at the time of infection might even increase the severity of retroviral disease, instead of preventing it. The experiments of Pedersen et al. (1986) demonstrate that these findings may have some implications in vivo; cats vaccinated with purified gpT0 or gp85 developed antibodies against both gpT0 and whole FeLV detectable by ELISA, but these antibodies did not neutralize the virus in vitro. These cats were more susceptible to infection with virulent FeLV or FeSV than non-vaccinated animals.
